SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
GAITHERSBURG, Md., Aug. 02, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and business progress.
Dial-in Information
U.S. Dial-In Number: (888) 883-4599
International Dial-In Number: (484) 653-6821
Conference ID: 61883667
Replay Dial-in Information
U.S. Dial-In Number: (855) 859-2056
International Dial-In Number: (404) 537-3406
Conference ID: 61883667
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor Contact: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 [email protected] or Bruce Voss 310-691-7100 [email protected]
